Dr Millie Das, MD opens a discussion surrounding updates regarding non-small cell lung cancer (NSCLC) as presented at the 2022 World Conference on Lung Cancer (WCLC).
World Conference on Lung Cancer 2022: Updates in NSCLC
IMpower010 trial data may influence a significant evolution in treatment of non–small cell lung cancer.
Millie Das, MD, shares key takeaways from her presentation regarding cost-effective strategies and payer considerations related to the treatment of NSCLC.
The HUDSON trial is explored by Dr Das as she provides an overview of the study and offers key considerations regarding results.
Millie Das, MD, outlines the JAVELIN Lung 100 trial and shares insights on strategies and data interpretation from the trial.
Dr Millie Das, MD discusses updates from the 2022 World Conference on Lung Cancer regarding non-small cell lung cancer (NSCLC).
Advertisement
Advertisement
Trending on AJMC
1
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
4
52-Week VERIFY Data Show Rusfertide Brings Sustained Responses in PV
5
